168 related articles for article (PubMed ID: 35512587)
41. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
42. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
[TBL] [Abstract][Full Text] [Related]
43. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
[TBL] [Abstract][Full Text] [Related]
44. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
45. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
[TBL] [Abstract][Full Text] [Related]
46. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
47. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C
Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519
[TBL] [Abstract][Full Text] [Related]
48. A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients.
Zheng K; Wan H; Zhang J; Shan G; Chai N; Li D; Fang N; Liu L; Zhang J; Du R; Wu Q; Li X; Zhang C
J Transl Med; 2020 May; 18(1):215. PubMed ID: 32466784
[TBL] [Abstract][Full Text] [Related]
49. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Romero JM; Grünwald B; Jang GH; Bavi PP; Jhaveri A; Masoomian M; Fischer SE; Zhang A; Denroche RE; Lungu IM; De Luca A; Bartlett JMS; Xu J; Li N; Dhaliwal S; Liang SB; Chadwick D; Vyas F; Bronsert P; Khokha R; McGaha TL; Notta F; Ohashi PS; Done SJ; O'Kane GM; Wilson JM; Knox JJ; Connor A; Wang Y; Zogopoulos G; Gallinger S
Clin Cancer Res; 2020 Apr; 26(8):1997-2010. PubMed ID: 31964786
[TBL] [Abstract][Full Text] [Related]
50. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.
Han MY; Borazanci E
J Gastrointest Oncol; 2023 Feb; 14(1):458-462. PubMed ID: 36915432
[TBL] [Abstract][Full Text] [Related]
51. Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.
Mo S; Ma X; Li Y; Zhang L; Hou T; Han-Zhang H; Qian J; Cai S; Huang D; Peng J
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859741
[TBL] [Abstract][Full Text] [Related]
52. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
[TBL] [Abstract][Full Text] [Related]
53. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
54. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
55. [Crosstalk of Cancer Genomic Test and Cancer Immune Therapy].
Nishihara H
Gan To Kagaku Ryoho; 2022 Mar; 49(3):248-254. PubMed ID: 35299175
[TBL] [Abstract][Full Text] [Related]
56. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
[TBL] [Abstract][Full Text] [Related]
57. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O; Tan W; Bryce AH; Dronca RS; Childs DS; Pagliaro LC; Orme JJ; Kase AM
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341460
[TBL] [Abstract][Full Text] [Related]
58. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
[TBL] [Abstract][Full Text] [Related]
59. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
[TBL] [Abstract][Full Text] [Related]
60. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.
Mosalem O; Coston TW; Imperial R; Mauer E; Thompson C; Yilma B; Bekaii-Saab TS; Stoppler MC; Starr JS
Oncologist; 2024 May; ():. PubMed ID: 38776551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
